|
Anxiolytic Effects of Socio-aesthetics in Cancer Patients Undergoing Chemotherapy
RECRUITINGN/ASponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche
Actively Recruiting
PhaseN/A
SponsorGCS Ramsay Santé pour l'Enseignement et la Recherche
Started2023-03-23
Est. completion2027-06-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05649852
Summary
The purpose of the study is to assess the average of the "State Anxiety" score of the State Trait Inventory Anxiety at the end of the third cycle of chemotherapy compared to the pre-treatment score (inclusion)
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: * Patient with cancer treated with adjuvant chemotherapy with an interval of 14 or 21 days for the first 3 cycles; * Chemotherapy naïve patient; * Patient speaking and understanding French and able to complete the questionnaires; * Patient having been informed and having signed an informed consent form to participate in the study. Exclusion Criteria: * Patient who has already benefited from socio-aesthetic care; * Protected patient (under legal protection, or deprived of liberty by judicial or administrative decision); * Patient unable to understand the information related to the study (linguistic, psychological, cognitive reasons, etc.); * Pregnant or likely to be pregnant (of childbearing age, without effective contraception) or breastfeeding; * Patient participating in another clinical trial, or in a period of exclusion from another clinical trial; * Patient not benefiting from a social security scheme.
Conditions2
CancerChemotherapy Effect
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhaseN/A
SponsorGCS Ramsay Santé pour l'Enseignement et la Recherche
Started2023-03-23
Est. completion2027-06-30
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →
NCT05649852